Hospital
The Children's Hospital of Alabama
The Children's Hospital of Alabama was paid $58.84M by Medicaid between Jan 2018 and Dec 2024, across 301 billing codes. Its largest line is G0463, Hospital outpatient clinic visit for assessment and management of a patient — 37% of everything it billed.
33Billing provider infoTHE CHILDREN'S HOSPITAL OF ALABAMA
BIRMINGHAM, AL 35233
BIRMINGHAM, AL 35233
33aNPI1205935012assigned 09/21/2006
33bProvider typeChildren's Hospital
28Total paid$58.84M
24GClaims1,362,453
24DCodes billed301
24AFirst – last monthJan 2018 – Dec 2024
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official WALTON, DAWN controls 19+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 201,742 | $6.91M | |
| 2019 | 216,676 | $7.87M | |
| 2020 | 134,576 | $5.25M | |
| 2021 | 172,428 | $7.41M | |
| 2022 | 181,303 | $9.25M | |
| 2023 | 242,250 | $11.45M | |
| 2024incomplete | 213,478 | $10.70M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 37% | 446,263 | 382,701 | $21.74M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 11% | 141,163 | 135,852 | $6.22M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 7.5% | 56,807 | 54,074 | $4.40M |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 6.1% | 1,975 | 1,552 | $3.61M |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | 5.5% | 23,890 | 11,169 | $3.26M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.2% | 7,681 | 7,374 | $2.48M |
| D9420 | 2.7% | 5,987 | 5,423 | $1.57M | |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | 2.6% | 3,897 | 3,517 | $1.55M |
| G0330 | Facility services for dental rehabilitation procedure(s) performed on a patient who requires monitored anesthesia (e.g., general, intravenous sedation (monitored anesthesia care) and use of an operating room | 2.3% | 1,411 | 1,389 | $1.36M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.2% | 18,114 | 17,338 | $733K |
| 42830 | 1.1% | 2,003 | 1,863 | $646K | |
| 80053 | Comprehensive metabolic panel | <1% | 46,563 | 40,409 | $585K |
289 more codes
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 59,179 | $578K |
| 95782 | <1% | 898 | $561K | |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 2,370 | $534K |
| 92567 | <1% | 32,751 | $454K | |
| 81229 | <1% | 428 | $387K | |
| 76770 | <1% | 9,422 | $385K | |
| 85055 | <1% | 14,928 | $383K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 25,650 | $373K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 731 | $365K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 7,156 | $311K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 1,290 | $305K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 999 | $276K |
| 17110 | <1% | 1,954 | $271K | |
| 36430 | <1% | 2,051 | $260K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 12,533 | $229K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 2,426 | $218K |
| 92579 | <1% | 9,535 | $181K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 15,202 | $176K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 4,986 | $176K |
| 83021 | <1% | 10,371 | $167K | |
| 94375 | <1% | 12,583 | $160K | |
| 86003 | <1% | 1,249 | $147K | |
| 86922 | <1% | 3,871 | $145K | |
| Q3014 | Telehealth originating site facility fee | <1% | 7,884 | $141K |
| 84439 | <1% | 13,936 | $139K | |
| 92555 | <1% | 11,176 | $134K | |
| 80061 | Lipid panel | <1% | 6,989 | $119K |
| 67311 | <1% | 513 | $101K | |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 791 | $81K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 6,602 | $80K |
| 85046 | <1% | 15,377 | $79K | |
| 92582 | <1% | 2,285 | $78K | |
| 82784 | <1% | 4,435 | $74K | |
| 80069 | <1% | 9,159 | $73K | |
| 81479 | Unlisted molecular pathology procedure | <1% | 50 | $72K |
| 83721 | <1% | 7,968 | $70K | |
| 92611 | <1% | 2,354 | $64K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 311 | $63K |
| 82977 | <1% | 9,109 | $63K | |
| 87497 | <1% | 1,761 | $59K | |
| 83970 | <1% | 991 | $59K | |
| 54161 | <1% | 258 | $56K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 2,004 | $55K |
| 82728 | <1% | 5,442 | $51K | |
| 43762 | <1% | 248 | $50K | |
| 95004 | Percutaneous tests with allergenic extracts, immediate type reaction | <1% | 2,784 | $49K |
| 82570 | <1% | 7,754 | $49K | |
| 92526 | <1% | 989 | $44K | |
| G0410 | Group psychotherapy other than of a multiple-family group, in a partial hospitalization or intensive outpatient setting, approximately 45 to 50 minutes | <1% | 201 | $43K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 2,012 | $41K |
| 85652 | <1% | 11,192 | $41K | |
| 83516 | <1% | 2,557 | $41K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 999 | $40K |
| 83880 | <1% | 1,315 | $40K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,138 | $39K |
| 80306 | <1% | 2,688 | $38K | |
| 95819 | <1% | 190 | $38K | |
| 87070 | <1% | 3,400 | $37K | |
| 74230 | <1% | 2,427 | $37K | |
| 81003 | <1% | 11,045 | $36K | |
| 95811 | <1% | 106 | $35K | |
| 86255 | <1% | 1,498 | $34K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 2,214 | $34K |
| 92552 | <1% | 2,012 | $33K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,571 | $33K |
| 82785 | <1% | 1,886 | $30K | |
| 92524 | <1% | 778 | $30K | |
| 83735 | <1% | 4,430 | $30K | |
| 82248 | <1% | 6,150 | $28K | |
| 72082 | <1% | 1,708 | $27K | |
| 70355 | <1% | 1,250 | $25K | |
| 94664 | <1% | 4,916 | $25K | |
| 86140 | <1% | 11,646 | $24K | |
| 74018 | <1% | 2,138 | $23K | |
| 73090 | <1% | 1,678 | $22K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,110 | $22K |
| 81001 | <1% | 5,090 | $21K | |
| 73562 | <1% | 758 | $20K | |
| 88185 | <1% | 247 | $20K | |
| 86850 | <1% | 3,397 | $19K | |
| 86945 | <1% | 661 | $19K | |
| 80076 | <1% | 2,107 | $18K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,176 | $17K |
| 80197 | <1% | 2,071 | $17K | |
| 92587 | <1% | 1,252 | $17K | |
| 93976 | <1% | 212 | $16K | |
| 90686 | <1% | 1,089 | $16K | |
| 77077 | <1% | 571 | $16K | |
| 84156 | <1% | 4,024 | $16K | |
| 96415 | <1% | 714 | $15K | |
| 70360 | <1% | 1,390 | $15K | |
| 83550 | <1% | 1,183 | $14K | |
| 82043 | <1% | 2,713 | $14K | |
| 84703 | <1% | 2,052 | $13K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 394 | $13K |
| 83615 | <1% | 2,108 | $12K | |
| 74019 | <1% | 812 | $12K | |
| 73630 | <1% | 776 | $12K | |
| 86905 | <1% | 2,298 | $12K | |
| 82803 | <1% | 378 | $11K | |
| 29075 | <1% | 294 | $10K | |
| 84100 | <1% | 2,702 | $10K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 479 | $10K |
| 85610 | <1% | 1,982 | $10K | |
| 72020 | <1% | 340 | $10K | |
| 86235 | <1% | 193 | $10K | |
| 86902 | <1% | 2,967 | $10K | |
| 96409 | <1% | 138 | $10K | |
| 80050 | General health panel | <1% | 212 | $9K |
| 86364 | <1% | 1,384 | $9K | |
| 83540 | <1% | 1,220 | $9K | |
| 86900 | <1% | 3,445 | $9K | |
| 86901 | <1% | 3,447 | $9K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 940 | $8K |
| 80074 | <1% | 201 | $8K | |
| 82652 | <1% | 154 | $8K | |
| 95816 | <1% | 176 | $8K | |
| 96401 | <1% | 227 | $7K | |
| 86038 | <1% | 412 | $7K | |
| 88230 | <1% | 46 | $7K | |
| 82947 | <1% | 1,216 | $7K | |
| 72081 | <1% | 451 | $7K | |
| 72170 | <1% | 494 | $7K | |
| 88184 | <1% | 247 | $6K | |
| 82550 | <1% | 884 | $6K | |
| 86317 | <1% | 159 | $6K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 1,700 | $6K |
| 73560 | <1% | 402 | $6K | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 12,700 | $6K |
| 87077 | <1% | 810 | $6K | |
| 73130 | <1% | 445 | $6K | |
| 80051 | <1% | 689 | $6K | |
| 83690 | <1% | 690 | $5K | |
| 84550 | <1% | 917 | $5K | |
| 86225 | <1% | 342 | $5K | |
| 88262 | <1% | 34 | $5K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 14,771 | $5K |
| 82150 | <1% | 610 | $5K | |
| 31575 | <1% | 16 | $5K | |
| 97161 | <1% | 91 | $4K | |
| 73140 | <1% | 443 | $4K | |
| 82465 | <1% | 630 | $4K | |
| 83655 | <1% | 284 | $4K | |
| 73070 | <1% | 323 | $4K | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 162 | $4K |
| 83718 | <1% | 630 | $4K | |
| 97016 | <1% | 230 | $4K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 27 | $3K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 90 | $3K |
| 83520 | <1% | 143 | $3K | |
| 85014 | <1% | 1,101 | $3K | |
| 86376 | <1% | 171 | $3K | |
| 82390 | <1% | 342 | $3K | |
| 82085 | <1% | 253 | $3K | |
| 73100 | <1% | 228 | $3K | |
| 82088 | <1% | 69 | $3K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 17,148 | $3K |
| 93888 | <1% | 40 | $3K | |
| 30802 | <1% | 16 | $3K | |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 26 | $3K |
| 86481 | <1% | 34 | $3K | |
| 83525 | <1% | 251 | $2K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,915 | $2K |
| 82103 | <1% | 255 | $2K | |
| 91065 | <1% | 60 | $2K | |
| 95117 | <1% | 200 | $2K | |
| 86162 | <1% | 111 | $2K | |
| 82104 | <1% | 143 | $2K | |
| 97760 | <1% | 104 | $2K | |
| 77072 | <1% | 243 | $2K | |
| 83519 | <1% | 199 | $2K | |
| 43760 | <1% | 15 | $2K | |
| 71045 | Radiologic examination, chest; single view | <1% | 394 | $2K |
| 64642 | <1% | 15 | $2K | |
| 95812 | <1% | 62 | $2K | |
| 91200 | <1% | 14 | $2K | |
| 86706 | <1% | 115 | $2K | |
| 73610 | <1% | 115 | $2K | |
| 83001 | <1% | 67 | $2K | |
| 85027 | <1% | 381 | $2K | |
| 83002 | <1% | 71 | $2K | |
| J2704 | Injection, propofol, 10 mg | <1% | 10,351 | $2K |
| 73590 | <1% | 105 | $2K | |
| 86160 | <1% | 45 | $2K | |
| 82670 | <1% | 53 | $1K | |
| 85007 | <1% | 378 | $1K | |
| 80180 | <1% | 121 | $1K | |
| 92553 | <1% | 109 | $1K | |
| 84244 | <1% | 56 | $1K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 33 | $1K |
| 87186 | <1% | 110 | $1K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 21 | $1K |
| 86708 | <1% | 90 | $1K | |
| 82105 | <1% | 55 | $968.44 | |
| 86341 | <1% | 51 | $921.67 | |
| 73552 | <1% | 64 | $911.68 | |
| 85730 | <1% | 338 | $878.92 | |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 26 | $876.36 |
| 82610 | <1% | 57 | $867.15 | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 1,678 | $829.45 |
| 86774 | <1% | 40 | $828.78 | |
| 86360 | <1% | 13 | $793.87 | |
| 86231 | <1% | 92 | $769.86 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 10,280 | $745.74 |
| 82525 | <1% | 58 | $712.85 | |
| 92610 | <1% | 40 | $691.44 | |
| 94200 | <1% | 84 | $691.29 | |
| 97162 | <1% | 16 | $652.20 | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 40 | $646.00 |
| 82533 | <1% | 26 | $632.94 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,131 | $630.53 |
| 73564 | <1% | 24 | $595.68 | |
| 82139 | <1% | 29 | $593.06 | |
| 82607 | <1% | 44 | $572.01 | |
| J9370 | Vincristine sulfate, 1 mg | <1% | 79 | $559.23 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 2,524 | $535.50 |
| 84403 | <1% | 14 | $515.10 | |
| 84630 | <1% | 29 | $455.00 | |
| 0002A | <1% | 13 | $440.00 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 68 | $423.01 |
| 86039 | <1% | 28 | $411.25 | |
| 85347 | <1% | 176 | $375.04 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 13 | $367.51 |
| 82330 | <1% | 81 | $364.86 | |
| 85018 | <1% | 142 | $364.01 | |
| 83921 | <1% | 18 | $332.08 | |
| 84305 | <1% | 27 | $310.04 | |
| 83090 | <1% | 25 | $308.36 | |
| 82747 | <1% | 25 | $308.36 | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 1,143 | $303.61 |
| 74240 | <1% | 13 | $288.18 | |
| 86406 | <1% | 24 | $280.93 | |
| 85379 | <1% | 26 | $280.75 | |
| 77073 | <1% | 12 | $277.31 | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 56 | $270.00 |
| 74455 | <1% | 12 | $256.95 | |
| 73521 | <1% | 14 | $224.38 | |
| 84446 | <1% | 14 | $222.12 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 20 | $220.11 |
| 86923 | <1% | 33 | $217.98 | |
| 70350 | <1% | 13 | $211.90 | |
| 84132 | <1% | 44 | $207.51 | |
| 84295 | <1% | 44 | $200.79 | |
| 82565 | <1% | 44 | $200.79 | |
| 86592 | <1% | 29 | $192.00 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 314 | $176.05 |
| 82435 | <1% | 44 | $167.04 | |
| 84590 | <1% | 13 | $141.96 | |
| 84484 | <1% | 12 | $134.76 | |
| 85384 | <1% | 12 | $134.52 | |
| 83605 | <1% | 13 | $133.20 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 28 | $77.87 |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 82 | $58.30 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 86 | $53.51 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 90 | $42.70 |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 932 | $33.90 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 182 | $1.30 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 1,229 | $0.78 |
| 82657 | 0% | 685 | $0.00 | |
| G0008 | Administration of influenza virus vaccine | 0% | 126 | $0.00 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | 0% | 592 | $0.00 |
| 95012 | 0% | 446 | $0.00 | |
| 11900 | 0% | 118 | $0.00 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | 0% | 379 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 204 | $0.00 |
| 92593 | 0% | 98 | $0.00 | |
| 87046 | 0% | 25 | $0.00 | |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | 0% | 13 | $0.00 |
| 87493 | 0% | 25 | $0.00 | |
| B4087 | Gastrostomy/jejunostomy tube, standard, any material, any type, each | 0% | 83 | $0.00 |
| 80230 | 0% | 37 | $0.00 | |
| 81332 | 0% | 12 | $0.00 | |
| 87209 | 0% | 23 | $0.00 | |
| 87328 | 0% | 327 | $0.00 | |
| 87799 | 0% | 1,656 | $0.00 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 24 | $0.00 |
| 92557 | 0% | 39 | $0.00 | |
| 92592 | 0% | 12 | $0.00 | |
| 87329 | 0% | 521 | $0.00 | |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | 0% | 47 | $0.00 |
| 86008 | 0% | 157 | $0.00 | |
| 87045 | 0% | 25 | $0.00 | |
| 87177 | 0% | 23 | $0.00 | |
| 87899 | 0% | 50 | $0.00 | |
| Q9958 | High osmolar contrast material, up to 149 mg/ml iodine concentration, per ml | 0% | 37 | $0.00 |
| 84460 | 0% | 14 | $0.00 | |
| 84450 | 0% | 14 | $0.00 | |
| 87327 | 0% | 156 | $0.00 | |
| 89055 | 0% | 25 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialWALTON, DAWN (CFO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.